flow trial semaglutide kidney outcomes Johannes Mann ending with a plug for the trial, the only dedicated renal outcome testing the effect of GLP1-RA (semaglutide) on a primary outcome of 50% decline in eGFR/ESKD/renal death # soul trial oral semaglutide cardiovascular

PlexusDx approaches this variation through genetic testing that may help identify predispositions in key peptide pathwaysinsights that can inform a more targeted conversation with your healthcare provider about which formulation, dose, and monitoring protocol might align with your metabolic profile

doi: 10.1038/ncomms6190

Key considerations include: The safety profile of weight loss injections in patients with dyslipidaemia Potential interactions with lipid-lowering medications The impact of weight loss itself on cholesterol levels Individual cardiovascular risk assessment Clinical evidence suggests that GLP-1 receptor agonists may have beneficial effects on lipid profiles beyond their primary weight loss action

The constipation makes sense given tirzepatides mechanism

Eating smaller, more frequent meals and avoiding lying flat right after eating can decrease both reflux and post-meal palpitations

Stopping too early can increase the chance of rebound hunger